Compare Qnity Electronics Inc. Common Stock (Q) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Qnity Electronics Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Qnity Electronics Inc. Common Stock trades at $118.33 (market cap $25.44B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Qnity Electronics Inc. Common Stock is far larger — about 3.5× Spyre Therapeutics Inc. Common Stock's market cap, and Qnity Electronics Inc. Common Stock pays a 0.26% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Qnity Electronics Inc. Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| Q | SYRE | |
|---|---|---|
Market Cap | $25.44B | $7.35B |
Volume | 1,971,734 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $175.64 | $108.92 |
52-Week Low | $73.54 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $28.50B | $6.35B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qnity Electronics (Q) trades at $122.95, down 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $4.75B in 2025, though net income margin is expected to dip in 2026. Recent news highlights product launches in AI data center cooling and advanced packaging, alongside inclusion in the PHLX Semiconductor Index.
The stock presents a mixed outlook: strong analyst consensus (100% buy ratings) and a $180 price target suggest significant upside, but technical weakness and a high P/E ratio of 43.9 pose risks. Key opportunities include AI-driven demand and advanced packaging growth, while risks involve execution in a competitive semiconductor market and potential margin pressure.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Qnity Electronics Inc. Common Stock
Qnity Electronics provides materials and solutions for semiconductor manufacturing and electronic systems. Its portfolio supports chip fabrication, advanced packaging, interconnects, and thermal management.
Read more on Q →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
